FDA Grants Orphan Drug Designation to Prestige BioPharma’s Anti-Cancer mAb
While there currently is no molecular therapy targeted against the PAUFgene, Prestige believes its monoclonal antibody has the potential to benefit patients affected by PAUF-positive pancreatic cancer.
Prestige BioPharma, a Singapore-based biopharmaceutical company, announced on June 30, 2020 that FDA has given orphan drug designation (ODD) to its first-in-class anti-pancreatic adenocarcinoma up-regulated factor (PAUF) monoclonal antibody (mAb), PBP1510, for the treatment of pancreatic cancer.
According to a company press release, the rapid expression of pancreatic cancer can be partially pinpointed to the PAUF gene. While there isn’t currently a molecular therapy targeted against PAUF, Prestige believes its mAb has the potential to benefit patients affected by PAUF-positive pancreatic cancer.
“The [o]rphan [d]rug [d]esignation we received from [FDA] is of significant importance in accelerating the development of PBP1510 to provide better treatment for pancreatic cancer, an extremely difficult to treat indication with a poor response to the currently available treatments,” said Dr. Lisa S. Park, CEO of Prestige BioPharma, in the press release.
Source: Prestige
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
